Let's break down Ajanta Pharma Limited (AJANTPHARM) — from its financial performance to how the market is valuing the stock.
Ajanta Pharma Revenue Trend
Ajanta Pharma Limited reported revenue of ₹4,743 Cr in FY2025, a 10.5% increase from ₹4,293 Cr in FY2024.
A 12.3% CAGR over 10 years puts Ajanta Pharma Limited in solid growth territory. The top line went from ₹1,481 Cr to ₹4,743 Cr in that span.
A ₹4,743 Cr revenue base makes Ajanta Pharma Limited a mid-sized name in the Indian pharmaceuticals sector.
With 6 straight years of revenue growth, this isn't a blip — the trajectory is clear for Ajanta Pharma Limited.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹4,743 Cr | +10.5% |
| FY2024 | ₹4,293 Cr | +11.8% |
| FY2023 | ₹3,841 Cr | +11.1% |
| FY2022 | ₹3,457 Cr | +18.6% |
| FY2021 | ₹2,916 Cr | — |
View Ajanta Pharma Limited's full 10-year revenue trend with CAGR analysis →
Ajanta Pharma Profitability
Ajanta Pharma Limited's bottom line improved to ₹920 Cr in FY2025, a 12.8% increase over the prior year.
The company maintained its net margin at 19.4% in FY2025, roughly in line with the prior year.
Per-share earnings moved to ₹73.53 in FY2025 from ₹64.77 in FY2024.
Is Ajanta Pharma Undervalued
Based on the P/E Ratio model, Ajanta Pharma Limited's fair value works out to ₹2,556 — 12.8% downside from where it trades today.
Ajanta Pharma Limited shares are currently trading at ₹2,929.20.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹2,556 | 12.8% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Ajanta Pharma Limited with detailed assumptions →
Ajanta Pharma Shareholding Pattern
No change in promoter stake — it has held at 66.2% for the past 4 quarters.
FII holding stands at 8.3%, down from 8.9% in the year-ago quarter.
DII holding is at 18.4%, up from 17.5% in the year-ago quarter.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 66.2% | 8.3% | 18.4% | 7.1% |
| Dec 2025 | 66.2% | 8.0% | 18.6% | 7.2% |
| Sep 2025 | 66.2% | 8.5% | 17.9% | 7.3% |
| Jun 2025 | 66.3% | 8.9% | 17.5% | 7.4% |
Track quarterly shareholding changes for Ajanta Pharma Limited →
Ajanta Pharma Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹50.15B (up 8.1% YoY from ₹46.38B).
Top categories: Property, Plant & Equipment (35.9%), Receivables (23.6%), Inventories (18.0%).
Of the ₹50.15B in liabilities and equity, 75.6% is shareholder equity, 0.9% is interest-bearing debt, and 23.5% is operating liabilities. Over the year, debt is up 34.4% and equity is up 6.2%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 6.14B |
| Receivables | 11.83B |
| Inventories | 9.04B |
| Property, Plant & Equipment | 18.01B |
| Investments | 252.40M |
| Intangibles & Goodwill | 465.20M |
| Other Assets | 4.42B |
| Category | Value |
|---|---|
| Equity | 37.90B |
| Short-term Debt | 127.00M |
| Long-term Debt | 347.20M |
| Trade Payables | 4.54B |
| Other Liabilities | 7.23B |
Ajanta Pharma Stock Analysis
To sum up Ajanta Pharma Limited's financial position: the data paints a clear picture for investors evaluating this pharmaceuticals stock.
Revenue of ₹4,743 Cr in FY2025, up 10.5% year-over-year.
Long-term revenue has been compounding at 12.3% annually over 10 years.
The company is profitable, with a net margin of 19.4% and net income of ₹920 Cr.
The P/E Ratio model implies 12.8% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Ajanta Pharma Limited.